Structure Therapeutics is trading at $46.45, down 4.2% today, as the stock undergoes profit-taking following a sharp multi-day rally driven by positive clinical data.
- The recent surge was fueled by positive Phase 2b data for aleniglipron, the company's oral GLP-1 candidate for obesity treatment.
- With no fresh company-specific headlines today and broader indices trading slightly higher, the move appears to be normal volatility following a period of bullish analyst sentiment.